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ABSTRACT: Nonsteroidal antiinflammatory drugs, including ibuprofen, are among the most commonly used med-
ications and produce their antiinflammatory effects by blocking cyclooxygenase (COX)-2. Their use is associated
with increased riskofheart attacks causedbyblockingCOX-2 in thevasculatureand/orkidney,withour recentwork
implicating the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA), a cardiotoxic hormone whose
effects can be prevented by L-arginine. The ibuprofen salt ibuprofen arginate (Spididol) was created to increase
solubility but we suggest that it could also augment the NO pathway through codelivery of arginine. Here we
investigated the idea that ibuprofenarginate can act to simultaneously inhibitCOX-2andpreserve theNOpathway.
Ibuprofen arginate functioned similarly to ibuprofen sodium for inhibition of mouse/human COX-2, but only
ibuprofen arginate served as a substrate for NOS. Ibuprofen arginate but not ibuprofen sodium also reversed the
inhibitory effects ofADMAandNG-nitro-L-argininemethyl ester on inducibleNOS (macrophages) andendothelial
NOS in vitro (aorta) and in vivo (blood pressure). These observations show that ibuprofen arginate provides, in one
preparation, a COX-2 inhibitor and NOS substrate that could act to negate the harmful cardiovascular conse-
quences mediated by blocking renal COX-2 and increased ADMA. While remarkably simple, our findings are
potentially game-changing in the nonsteroidal antiinflammatory drug arena.—Kirkby, N. S., Tesfai, A., Ahmetaj-
Shala, B., Gashaw, H. H., Sampaio, W., Etelvino, G., Leão, N. M., Santos, R. A., Mitchell, J. A. Ibuprofen arginate
retains eNOS substrate activity and reverses endothelial dysfunction: implications for the COX-2/ADMA axis.
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Nonsteroidal antiinflammatory drugs (NSAIDs) are the
most commonly taken over-the-counter medications for
the treatment of pain and inflammation, with ibuprofen
representing a significant share of themarket. All NSAIDs
work by blocking cyclooxygenase (COX) enzymes. COX
has 2 isoforms: a constitutive form, COX-1, which is
ubiquitously expressed, andCOX-2, which is an inducible
isoform rapidly expressed at the site of inflammation and
in cancer. However, COX-2 is expressed constitutively
without inflammation indiscrete regionsof the body (1, 2).
These areas include the brain, thymus, gut, and kidney
(1, 2). Inhibition of inducible COX-2 activity explainsmost
of the therapeutic benefit of NSAIDs (antiinflammatory,
analgesic, antipyretic); however, inhibition of constitu-
tively expressed COX-2 by NSAIDs, including ibuprofen,
causes adverse effects that limit their use (3). Upper gas-
trointestinal adverse effects associated withNSAID usage
are due to the combined inhibition of COX-1 and -2 (4) but
are relatively well managed by the use of selective COX-2
NSAIDs and coadministration of proton pump inhibitor
drugs.However,NSAID-associated cardiovascular effects
remain a major clinical concern. Initially, authorities such
as the American Heart Association considered cardio-
vascular toxicity to be an issuemainly for COX-2 selective
NSAIDs (5). However, because all NSAIDs work by
blocking COX-2 (6), we and others suggested that car-
diovascular toxicity is a class effect (7), an idea that is now
universally accepted (8). The risk of cardiovascular ad-
verse effects associated with blocking COX-2 has resulted
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in a series of regulatory events, including: 1) the with-
drawal of the blockbuster drug Vioxx in 2004, 2) the in-
troduction of black box warnings on some NSAIDs from
2005 and on all drugs in this class since 2015, 3) the with-
drawal of celecoxib (Onsenal) for the prevention of cancer
in 2011, and 4) the reclassification of the over-the-counter
medication diclofenac as prescription only in 2015 (UK).
Now the fear of cardiovascular events caused by NSAIDs
has resulted in the cautious prescribing of COX-2 selective
drugs (9) in favor of older-style medications, which are
more toxic to the gut, and a failure to realize the full clinical
potential of NSAIDs in the prevention of cancer (10).
While themechanismsthatmediate cardiovascular side
effects of blocking COX-2 are incompletely understood,
they are thought to involve blocking the release of car-
dioprotective lipid mediators (prostanoids) including
prostacyclin from endothelial cells (11) or in the kidney
(12, 13). Our recent work has shown that constitutively
expressed COX-2 in the kidney provides a powerful
regulation of the methylarginine system (12). Methyl-
arginines, such as L-NG-monomethyl arginine (L-NMMA)
and asymmetric dimethylarginine (ADMA), are naturally
occurring molecules formed when arginine residues in
proteins are methylated and subsequently broken down
(14, 15). L-NMMA and ADMA act as competitive inhibi-
tors with the natural substrate L-arginine at the active site
of the enzyme NOS (15). In this way, L-NMMA and
ADMA can compromise systemic cardiovascular health
by blocking the NO release in blood vessels that contrib-
utes to vasodilation, platelet inhibition, and protection
against atherosclerosis. Our work strongly indicates
ADMA acts as a biomarker and mechanistic bridge be-
tween inhibition of COX-2 by NSAIDs and vascular dys-
function. We found increased plasma ADMA levels in
COX-2-deficient mice and in wild-type mice or healthy
human volunteers treated with COX-2 inhibitors (12).
ADMA is also increased in the plasma of arthritis patients
(16), themajority of whomwill be takingNSAIDs (16, 17).
This idea has credibility within the cardiovascular field
because ADMA is an established cardiovascular bio-
marker in both preclinical and clinical studies and, impor-
tantly, is associated with some indicators of cardiovascular
disease (18)anddeath (19) in largecohort studiessuchas the
FraminghamHeart Study. Importantly, if our hypothesis is
correct, the cardiovascular toxicity in susceptible NSAID
users could be prevented by administration of L-arginine,
which would counteract the effects of ADMA through
competition for the active site of NOS.
Ibuprofen is one of the most commonly used non-
prescription NSAIDs, and this is set to increase with the
reclassification of over-the-counter diclofenac (United
Kingdom)andwith thevirtualarrest (due to concernsover
adverse effects) of new drug development in this class.
Ibuprofen is relatively slowly absorbed in the gut, but
several formulations have been developed to accelerate
absorption, including combining ibuprofen as a salt with
basic amino acids such as lysine (20) and arginine (21).
Pharmaceutical ibuprofen arginate marketed by Zambon
Pharma (Lonigo, Italy) under the trade names Spididol,
Spedifen, Espididol, and Faspic takes the form of a prep-
aration with 1:1 molar ratio of ibuprofen and arginine.
As with all salts, once in solution, ibuprofen and arginine
will dissociate, and so ibuprofen arginate should deliver
arginine to function inan identicalmanner toother sources
of arginine. At the maximum recommended doses of
ibuprofen of up to 2.4 g per day, this would equate to
administration of ;2 g of arginine, an amount that has
been shown to produce beneficial cardiovascular effects in
humans (22). As such, in addition to its improved phar-
macokineticsvs. free ibuprofen, ibuprofen arginate has the
potential to provide an effective COX-2 inhibitor and
substrate for NO in one clinically approved pharmaceu-
tical preparation.While ibuprofen arginate has, in a single
previous study, been shown to release NO (23), the idea
that it can substitute for L-arginine and/or reverse the
effects of substrate inhibitors in a setting of NSAID car-
diovascular toxicity has simply not been previously
considered.
To explore this idea, we systematically studied the 2
putative pharmacological possibilities of ibuprofen
arginate—inhibition of COX-2 and rescue of the NOS
pathway—in conditions where extracellular arginine is
low and where intracellular arginine is limited by the
presenceofsubstrate inhibitors includingADMA,L-NMMA,
and L-nitro-arginine methyl ester (L-NAME).
MATERIALS AND METHODS
In vitro studies
RAW264.7 cells and A549 cells were purchased from American
Type Culture Collection (Manassas, VA, USA) and cultured in
either arginine-free DMEM (Thermo Fisher Scientific Life Sci-
ences, Waltham, MA, USA) or standard DMEM (containing
400 mM L-arginine; Sigma-Aldrich, St. Louis, MO, USA), both
supplemented with fetal calf serum (10%; LabTech, Uckfield,
United Kingdom). Confluent cultures were treated with LPS
(RAW264.7 cells; 1 mg/ml; Sigma-Aldrich) or IL-1b (A549 cells;
10 ng/ml; R&D Systems, Minneapolis, MN, USA) for 24 h to
induce iNOS and COX-2, in some cases in the presence of the
NOS inhibitors, L-NAME (300 mM; Sigma-Aldrich) or ADMA
(1 mM; Sigma-Aldrich). Increasing concentrations of ibuprofen
arginate (Zambon Pharma), ibuprofen sodium (Sigma-Aldrich),
L-arginine free base (Sigma-Aldrich), or the combination of ibu-
profen sodium and L-arginine were also added such that the
molar concentration of L-arginine present in each preparation
was the same, or for ibuprofen sodium, the molar concentration
of ibuprofen.After 24h,mediawere collected formeasurementof
nitrite accumulation using theGriess reaction (Sigma-Aldrich) or
PGE2using immunoassay (Cisbio,Codolet, France).Cell viability
was assessed using the alamarBlue metabolic activity assay
(Thermo Fisher Scientific).
Animals
Experiments were performed on male 8 wk old C57BL/6 mice
andWistar Kyoto rats, both bred at the Biologic Science Institute
(CEBIO, Federal University of Minas Gerais, Belo Horizonte,
Brazil). Animals were housed with a 12 h light/dark cycle with
free access to water and standard rodent chow. All animal ex-
perimentswere conducted in linewithEUdirective 2010/63/EU
and subject to ethical review by the Imperial College Ethical
Review Board (PPL 70/8422) and/or the Federal University of
Minas Gerais Animal Care Committee.
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Isolated vessel studies
Mice or ratswerehumanely killed by cervical dislocation and the
thoracic aorta carefully removed and cleaned of periadventitial
fat. Mouse and rat aortas were loaded into organs baths con-
taining Krebs buffer (composition: 120 mM NaCl; 4.7 mM KCl;
1.2 mM MgSO4; 1.2 mM KH2PO4; 25 mM NaHCO3; 0.03 mM
EDTA; 5.5 mM D-glucose; Sigma-Aldrich) at 37°C. Diclofenac
(10 mM; Novartis, Basel, Switzerland) was added to the Krebs
buffer to block vascular prostanoid formation that could con-
found interpretation of the effect of arginine preparations.
Changes in force under a resting tension of ;10 mN were
recorded via an isometric force transducer (mouse aorta; DMT,
Aarhus, Denmark; rat aorta, World Precision Instruments,
Sarasota, FL, USA) connected to a digital signal acquisition
system (ADInstruments, Dunedin, New Zealand).
Aortas were precontracted with a submaximal concentration
of phenylephrine (mouse 100 nM; rat 60 nM; Sigma-Aldrich). For
mouse vessels, L-NAME (200 mM) was then added to produce
contraction driven by reduced NO caused by arginine in-
sufficiency.Once the resulting L-NAME-induced contractionhad
stabilized, increasing concentrations of either ibuprofen arginate
(0.4–2 mM) or an equimolar amount of ibuprofen sodium was
added to the bath. For rat vessels, after precontraction, acetyl-
choline (10 mM; Sigma-Aldrich) was added to stimulate endo-
thelial NO production. For reversal protocols in rat vessels,
the acetylcholine-induced dilationwas blocked by addition of
L-NAME (100 mM), and once the response stabilized, increasing
concentrations of either ibuprofen arginate (0.4–2 mM) or an
equimolar amount of ibuprofen sodiumwere added to the bath.
For prevention protocols in rat vessels, either ibuprofen arginate
(1mM) or ibuprofen sodium (1mM)were added to the bath and
incubated for 5 min before the addition of increasing concentra-
tions of L-NAME (1–100 mM).
In vivo blood pressure experiments
Rats were anesthetized with urethane (1.2 g/kg i.p.; Sigma-
Aldrich) and tracheotomized. The left femoral artery was can-
nulated with polyethylene tubing and connected to a pressure
transducer and signal acquisition system (Biopac Systems,Golta,
CA, USA) for continuous arterial pressure recording. The left
femoral veinwas cannulated for administration of all subsequent
drugs. Diclofenac (1 mg/kg) was administered to remove con-
founding effects of vascular prostanoid formation and blood
pressureallowed tostabilize for10min.Forpreventionprotocols,
saline, L-arginine free base, ibuprofen sodium, or ibuprofen
arginate were administered (each at 57.4 mmol/kg; equivalent
to 10 mg/kg L-arginine, assuming full dissociation), and after
10 min, increasing concentrations of L-NAME (0.03–30 mg/kg;
3 min interval) were given. For reversal protocols, L-NAME
(0.5 mg/kg) was administered and the pressor effect allowed to
stabilize for 5 min before the ability of ibuprofen sodium or ibu-
profen arginate (each at 114.8 mmol/kg; equivalent to 20 mg/kg
L-arginine assuming full dissociation) to reverse this was
determined.
Statistical and data analysis
Data are presented asmeans6 SEM for n experiments. Datawere
analyzed using 1- or 2-way ANOVAwith Sidak’s post hoc test
as indicated in the individual figure captions, and data were
considered significant at P , 0.05. Analysis was performed
by GraphPad Prism software (GraphPad Software, La Jolla,
CA, USA).
RESULTS AND DISCUSSION
NSAIDs, including ibuprofen, owe their therapeutic ef-
fects to inhibition of COX-2. In order to first define the
NSAID properties of ibuprofen arginate, we compared its
potency for COX-2 inhibition to ibuprofen sodium. Using
COX-2 induced in murine macrophages (24) (RAW264.7
cells) and human lung epithelial cells (25–28) (A549 cells)
treated with inflammatory stimuli (LPS or IL-1b re-
spectively), we observed that ibuprofen arginate had no
effect on cell viability at concentrations up to 300 mM)
(percentage control: RAW264.7, 119.26 1,5;A549, 103.06
2.1) and was equipotent to ibuprofen sodium on a molar
basis for inhibiting human and mouse COX-2-dependent
PGE2 formation (Fig. 1). This is consistent with the free
dissociation of ibuprofen arginate to ibuprofen and argi-
nine components in solution.
We next examined the ability of the arginine compo-
nent of ibuprofen arginate to provide substrate for NOS.
In plasma, arginine is present within the range of 50 to
100 mM (29) but can be .40-fold greater within vascular
tissues (30). As a result of this, under normal conditions,
arginine is not rate limiting for NO production (30–34).
However, free arginine levels can become rate limiting
under conditionswhere arginine is absent (35) or depleted
(31), or in the presence of substrate inhibitors including
ADMA (15), L-NMMA (endogenous methylarginines),
Figure 1. Ibuprofen arginate inhibits COX-2 in
mouse (A) and human (B) cells. PGE2 release
from mouse RAW264.7 cells (A) stimulated
with LPS (1 mg/ml) and human A549 cells (B)
stimulated with IL-1b (10 ng/ml) to induce
COX-2. Data are presented as means 6 SEM
for n = 4. P . 0.05 by 2-way ANOVA for all
comparisons.
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and L-NAME (a synthetic inhibitory arginine analog)
(34–36).
Mouse macrophages express iNOS when stimulated
with LPS in culture, and this can be quantified by mea-
suring the formation of nitrite (35). As expected, mouse
macrophages released high levels of PGE2 (Fig. 1) and
nitrite (23.1 6 1.6 mM) when stimulated with LPS in
regular DMEM media. Because DMEM (like most cul-
ture media) contains relatively high levels of arginine,
;400 mM, iNOS is saturated with excess substrate in this
system. However, when arginine was removed from the
media, nitrite was negligible (Fig. 2). Nitrite release could
be restored by the addition of arginine in the form of ar-
ginine HCl or in the form of ibuprofen arginate (Fig. 2).
Addition of ibuprofen sodium, however, had no effect on
nitrite levels when given to LPS stimulated mouse
macrophages in arginine-free media (Fig. 2). This di-
rectly demonstrates that the arginine delivered by
ibuprofen arginate is able to act as substrate for NOS in
the absence of other substrate.
We next studied whether ibuprofen arginate could
rescue NOS activity in the presence of naturally oc-
curring (ADMA, L-NMMA) or synthetic (L-NAME)
substrate inhibitors through competition of the active
site of iNOS. These NOS inhibitors—ADMA, L-NMMA,
and L-NAME—produced concentration-dependent re-
ductions in nitrite levels released by LPS-stimulated
mouse macrophages when cultured in normal, arginine-
replete culture media (data not shown). In each case,
supplementation of the media with arginine HCl or ibu-
profen arginate, but not ibuprofen sodium, reduced the
efficacy of ADMA, L-NMMA, and L-NAME (Fig. 3),
demonstrating that in an iNOS system, ibuprofen arginate
can rescue NO dysfunction produced by endogenous
NOS inhibitors.
In blood vessels, where NO acts as a cardioprotective
mediator, NO is synthesized from arginine by the
endothelial form of NOS (eNOS) (37), which is highly
enriched in endothelial cells (37). Unlike iNOS, eNOS re-
quires calcium for activation (37). To profile the ability of
the arginine function of ibuprofen arginate to drive eNOS
activity, we used 2 well-defined eNOS bioassay systems.
First, we used mouse aorta. After stimulation with the
contractile agonist phenylephrine to provide tone, vessels
were treated with L-NAME, which produces a further
contraction of the vessel in response to inhibition of basal
NO release through eNOS. Within this system, arginine
supplementation competes with L-NAME to restore basal
NO release. We found that ibuprofen arginate, but not
ibuprofen sodium, produced concentration-dependent
reversal of the contraction causedbyL-NAME(Fig. 4). This
was a specific effect on L-NAME-induced contraction be-
cause neither ibuprofen arginate nor ibuprofen sodium
reversed contraction of mouse aorta induced the throm-
boxane mimetic U46619 (Fig. 4).
Second, we used a classic pharmacologic bioassay for
demonstration of eNOS activity (38). In rat aorta con-
tracted with phenylephrine to provide a basis for vasodi-
lation, the endotheliumwas stimulatedwith acetylcholine
to activate eNOS, which produced an almost complete
antagonism of the contraction caused by phenylephrine.
In this model, because arginine is in excess within the tis-
sue, addition of exogenous arginine has minimal effect on
eNOS responses. However, intracellular levels of arginine
can be made rate limiting by the addition of arginine
substrate inhibitors such as L-NAME. In this setting, ad-
dition of L-NAME can produce a complete reversal of
the eNOS-driven relaxation as a result of its competition
with arginine for the active site of eNOS (39). This reflects
a situation within the endothelium comparable to an
arginine-free environment in which eNOS activity can
be revealed by the subsequent addition of arginine (39).
Under these conditions, preincubation of vessels with
ibuprofen arginate but not ibuprofen sodium reduced
the ability of L-NAME to reverse acetylcholine-induced
vasodilation of phenylephrine precontracted rat aortic
rings (Fig. 5A, B). Correspondingly, when added after
L-NAME, addition of ibuprofen arginate but not ibu-
profen sodium was able to reverse an established
contraction of rat aortic rings driven by arginine in-
sufficiency (Fig. 5C, D). These data firmly demonstrate
that ibuprofen arginate can restore eNOS, as well as
iNOS activity in situations where substrate availability
is limited in vitro.
Last, we studied whether ibuprofen arginate exhibits
similar arginine substrate activity for eNOS responses
when administered in vivo. As in isolated vessels, arginine
concentrations in vivo are not rate limiting for vascular
eNOS activity. Therefore, to test arginine substrate activ-
ity of ibuprofen formulations in vitro, we produced ex-
perimental arginine insufficiency by administration of
L-NAME to anesthetized rats. This produces a predictable
increase in blood pressure that is driven by loss of eNOS-
dependent vasodilator tone and is sensitive to arginine
supplementation (40). In this model, pretreatment of rats
with L-arginine free base or ibuprofen arginate, but not
ibuprofen sodium, prevented L-NAME-induced pressor
responses (Fig. 6A, B). Similarly, when administered to
Figure 2. Ibuprofen arginate serves as substrate for NO
production. NO production was measured as nitrite accumu-
lation from mouse RAW264.7 cells cultured in arginine-free
media and stimulated with LPS (1 mg/ml) to induce iNOS.
Data are presented as means 6 SEM for n = 4. *P , 0.05 vs.
L-arginine by 2-way ANOVA with Sidak’s posttest.
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rats that were first treated with L-NAME, ibuprofen argi-
nate but not ibuprofen sodium could reverse the estab-
lished blood pressure increase. Taken together, these
observations demonstrate that ibuprofen arginate can
support eNOS activity both in vitro and in vivo.
Thus, ibuprofen arginate in solution serves as both an
effective inhibitor of COX-2 and a substrate for NOS in
vitro and in vivo. In our previous work where we found
COX-2 inhibition increases plasmaADMA,we also found
that this resulted in reduced eNOS responses in the sys-
temic circulation that could be rescued by the addition
of L-arginine (12). We suggested that L-arginine sup-
plementation could therefore provide an effective res-
cue therapy for COX-2 inhibitor cardiovascular toxicity
and that a prospective clinical trial would be needed to
validate our hypothesis (12). However, such a trial
would be expensive, difficult to power, and would in-
volve lengthy considerations regarding formulations.
Our findings here are not surprising because ibuprofen
arginate is a simple salt that in solution will dissoci-
ate into ibuprofen and arginine. Nonetheless, because
ibuprofen arginate was formulated for its pharmacokinetic
Figure 4. Ibuprofen arginate reverses contraction induced by eNOS inhibition (A, B) but not thromboxane (C, D) in mouse aorta.
Contraction of mouse aortic rings induced by L-NAME after phenylephrine (PE) precontraction (A, B) or induced by U46619
(C, D). Representative traces (A, C) and quantiﬁed data (B, D). Data are presented as means 6 SEM for n = 4–8 vessels from 4
mice. *P , 0.05 by 2-way ANOVA.
Figure 3. Ibuprofen arginate reverses inhibition
of iNOS produced by L-NAME (A) and ADMA
(b). NO production was measured as nitrite
accumulation from mouse RAW264.7 cells cul-
tured in arginine-replete medium and stimu-
lated with LPS (1 mg/ml) to induce iNOS in
presence of ADMA (A) or L-NAME (B). Data are
presented as means6 SEM for n = 4. *P, 0.05 vs.
vehicle by 1-way ANOVA with Sidak’s posttest.
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benefits (over ibuprofen acid), considerations of its
potential to protect from NSAID-induced cardiovas-
cular toxicity have simply never been considered
before.
Thus, while remarkably simple, our findings that ibu-
profen arginate has that ability to rescue eNOS dys-
function, such as might be produced by ADMA after
inhibition of renal COX-2 by the NSAID component of
this medication, have the potential to be globally game
changing in the NSAID arena. As such, we suggest that
ibuprofen arginate—an approved, clinically used, and
freely available NSAID formulation—has great prom-
ise to spare the cardiovascular toxicity associated with
use of drugs that inhibit COX-2. The next steps to
translate this idea to the clinic would be to perform
experiments in animalmodels of cardiovascular disease
Figure 5. Ibuprofen arginate prevents (A, B) and reverses (C, D) L-NAME-induced endothelial dysfunction in rat aorta. Rat
aortic rings were stimulated to produce NO by acetylcholine, and then ibuprofen formulations were added either before (A, B)
or after (C, D) L-NAME. Representative traces (A, C) and quantiﬁed data (B, D). Data are presented as means6 SEM for n = 4 rats.
*P , 0.05 by 2-way ANOVA.
Figure 6. Ibuprofen arginate prevents and reverses acute L-NAME-induced pressor responses in rat in vivo. L-NAME-induced
arterial blood pressure increases in anesthetized rats where ibuprofen/arginine formulations are administered either before (A, B) or
after (C) L-NAME. Data are presented as means 6 SEM for n = 3–4 rats. *P , 0.05 by 2-way ANOVA (A, B) or 1-way ANOVA (C).
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known to be sensitive to COX-2 inhibition, such as
atherosclerosis (41) and thrombosis (42), and to com-
pare the effects of ibuprofen arginate with ibuprofen so-
dium in healthy human subjects where arginine, ADMA,
and endothelial/platelet function are measured.
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